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Introduction

Author affiliations and article information are
listed at the end of this article.

The US Preventive Services Taskforce (USPSTF) broadened lung cancer screening (LCS) eligibility in
March 2021, lowering the minimum age to 50 years and decreasing smoking intensity to 20
pack-years.1 The expanded criteria have been projected to double the number of individuals with
high risk eligible for LCS with low-dose computed tomography and further reduce lung cancer
mortality.2,3 Moreover, the updated criteria may improve screening eligibility among vulnerable
individuals, including African American, Hispanic, and female patients, and individuals who identify
as members of the lesbian, gay, bisexual, transgender, queer, intersex, asexual communities as well as
gender nonconforming individuals, who have previously experienced disproportionate
underscreening.3 Specifically, African American individuals are less often eligible for LCS despite
developing lung cancer at younger ages and with lower smoking intensity.1 Studies estimating the
population-level outcomes associated with these changes in national cohorts have demonstrated
mixed results with regard to relative increases in screening eligibility among racial and ethnic
minorities, including African American individuals, and other underserved groups.2,4,5 There is a gap
in knowledge about the directly observed impact of the USPSTF 2021 guidelines on LCS uptake in
diverse populations. This study aims to begin to fill this gap by characterizing differences among
individuals deemed eligible under USPSTF 2013 vs under USPTSF 2021 guidelines undergoing LCS in
a centralized program.

Methods
This cross-sectional study was approved by the Thomas Jefferson University institutional review
board and granted a waiver of informed consent because this was a minimal risk, retrospective study
of individuals already in our LCS Program Registry. We followed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting guideline.
Individuals who completed LCS between March 9 and December 9, 2021, through our
centralized program at an urban, academic medical center were identified in our LCS Program
Registry. This group was divided into a USPSTF 2013–eligible cohort (age ⱖ55 years and ⱖ30 packyears, and quit <15 years ago) vs a USPSTF 2021–eligible cohort (age 50-54 years or 20-29 packyears, and quit <15 years ago). Race, ethnicity, and gender were determined through self-report. For
the purposes of this study examining race, race was recoded to African American, White, and other,
which included individuals who identified as Alaskan Native or American Indian, Asian, Native
Hawaiian or Pacific Islander, and more than 1 race. An historical cohort from the same 9-month period
in 2019 was identified for additional comparison. Descriptive statistics, independent t tests, and χ2
tests were performed using a P < .05 significance threshold. Statistical analyses were 2-sided and
conducted using SPSS statistical software version 26 (IBM) from December 13 to 16, 2021.
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Results
Baseline characteristics of the 815 individuals (mean [SD] age, 63.71 [5.98] years; 466 [57.2%]
women) screened during the study period are displayed in the Table, including 161 patients (19.8%)
who were newly eligible by USPSTF 2021 criteria and 654 individuals (80.2%) eligible under 2013
criteria. This USPSTF 2021–eligible cohort had a significantly greater proportion of African American
individuals than the USPSTF 2013–eligible cohort (54.0% vs 39.5%; P = .002) (Table). Newly eligible
individuals more frequently reported current smoking status (65.2% vs 55.0%; P = .02). As
expected, individuals eligible under USPSTF 2021 criteria had a lower frequency of Medicare
insurance and a significantly lower mean PLCOm2012 lung cancer risk (a lung cancer risk prediction
model derived from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and modified
using National Lung Screening Trial data by Tammemagi and colleagues6) compared with the cohort
eligible under USPSTF 2013 criteria. There was no significant difference in gender, distribution of
educational attainment, or Lung Imaging Reporting and Data System (Lung-RADS) results between
participants eligible under 2013 vs 2021 criteria. Comparison of the USPSTF 2013–eligible cohort

Table. Baseline Characteristics of Individuals Undergoing Lung Cancer Screening Between
March 9 and December 9, 2021
USPSTF eligibility criteriaa
Characteristic

2021 (n = 161)

2013 (n = 654)

P value

Age, mean (SD), y

59.00 (6.02)

64.87 (5.37)

<.001

Women

97 (60.2)

369 (56.4)

Men

64 (39.8)

285 (43.6)

African American

87 (54.0)

258 (39.5)

White

64 (39.8)

357 (54.7)

Otherb

10 (6.2)

38 (5.8)

Current

105 (65.2)

360 (55.0)

Former

56 (34.8)

294 (45.0)

Gender
.38

Race

.002

Smoking status
.02

Pack-years, mean (SD)

36.86 (18.20)

52.40 (22.88)

<.001

Personal history of cancer

15 (9.3)

102 (15.8)

.11

Family history of lung cancer

42 (26.1)

175 (26.8)

.98

COPD

42 (26.1)

271 (41.4)

<.001

<High school diploma

24 (14.9)

85 (13.0)

High school diploma/GED

70 (43.5)

289 (44.2)

>High school diploma

64 (39.8)

256 (39.1)

Unknown

3 (1.9)

24 (3.7)

Medicare

28 (17.4)

259 (39.6)

Medicaid or dual eligible

62 (38.5)

161 (24.6)

Private

64 (39.8)

211 (32.3)

3 (2.6)

23 (3.5)

3.27 (4.40)

6.64 (6.37)

1

54 (33.5)

236 (36.1)

2

74 (46.0)

306 (46.8)

3

17 (10.6)

55 (8.4)

Education

.65

Abbreviations: COPD, chronic obstructive pulmonary
disorder; GED, General Educational Development;
Lung-RADS, Lung Imaging Reporting and Data System;
USPSTF, US Preventive Services Task Force.
a

The USPSTF-eligible cohorts are comprised of
individuals who were eligible and underwent lung
cancer screening.

b

Includes individuals who self-identified as Alaskan
Native or American Indian, Asian, Native Hawaiian or
Pacific Islander, or more than 1 race.

c

The PLCOm2012 model is a lung cancer risk
prediction model derived from the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial and
modified using National Lung Screening Trial data by
Tammemagi and colleagues.6

d

Due to the small sample size in the USPSTF 2021–
eligible cohort, the expected count for not assigned
under Lung-RADS, and a lung cancer diagnosis under
screen-detected lung cancer diagnosis was fewer
than 5. Therefore, the statistical significance result
from the χ2 test may not be valid.

Insurance status

Other or none
c

PLCOm2012 lung cancer risk, mean (SD)

<.001

<.001

Lung-RADS

4A, 4B, 4X

10 (6.2)

41 (6.3)

Not assigned

6 (3.7)

16 (2.4)

0

12 (1.8)

Screen-detected lung cancer diagnosis
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screened in 2021 with a historical cohort screened in 2019 demonstrated no significant differences
in age, gender, race or ethnicity, smoking history, PLCOm2012 risk, or Lung-RADS distribution.

Discussion
This cross-sectional study of LCS uptake found that a significantly higher proportion of African
American individuals were screened through our centralized LCS program after implementation of
the expanded USPSTF 2021 criteria, but this was not observed among women or individuals with low
educational attainment. Characterization of newly eligible and screened individuals is critical, as
African American individuals, women, and other populations previously experiencing
underscreening may in fact receive a greater lung cancer mortality benefit from LCS compared with
White men.2,3 Although revision of the USPSTF criteria initially spurred optimism for more equitable
screening, some population-based studies have noted that expanded eligibility may paradoxically
serve to perpetuate racial, ethnic, and other disparities.4,5 LCS is a complex process with a multitude
of potential barriers, and social determinants of health care, such as insurance status and access to
care, may continue to disproportionately limit access to screening services for underserved
populations.4
Limitations of this study include its single-institution design and a low rate of individuals
reporting being a minority race or ethnicity other than African American. Future studies should
examine USPSTF 2021–driven changes in LCS uptake as a function of relative changes in LCS
eligibility to more completely define the impacts of the expanded criteria. Additional research is also
needed in selection of LCS candidates using prediction models for lung cancer risk or life-years
gained, which may improve screening efficiency for some groups, including those with lung cancer
risk factors but who are ineligible for LCS.5
Expansion of screening criteria is a critical first step to achieving equity in LCS for all high-risk
populations, but myriad challenges remain before individuals enter the door for screening. Health
policy changes must occur simultaneously with efforts to expand community outreach, overcome
logistical barriers, and facilitate screening adherence. Only after comprehensive strategies to
dismantle screening barriers are identified, validated, and implemented can there be a truly equitable
landscape for LCS.
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